Novel therapeutic targets for the treatment of tubulointerstitial fibrosis

Current Signal Transduction Therapy

Volumn 3, Issue 2, 2008, Pages 97-111

  Prakash, Jai ^a   Poelstra, Klaas ^a   van Goor, Harry ^b   Moolenaar, Frits ^a   Meijer, Dirk K F ^a   Kok, Robbert J ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Drug targeting; Inflammation; Kidney; Kinase inhibitors; Signal transduction; Tubulointerstitial fibrosis

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; ADENOVIRUS VECTOR; AMG 548; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CC 401; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DORAMAPIMOD; FASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NAPROXEN; RECOMBINANT SCATTER FACTOR; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HYPOXIA; KIDNEY FIBROSIS; KIDNEY FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; RENAL PROTECTION; RENOVASCULAR HYPERTENSION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TISSUE INJURY; TUBULOINTERSTITIAL FIBROSIS;

EID: 54949148355     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436208784223161     Document Type: Review

References (224)

1. el Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-40.
2. el Nahas AM, Muchaneta-Kubara EC, Essawy M, Soylemezoglu O. Renal fibrosis: insights into pathogenesis and treatment. Int J Biochem Cell Biol 1997; 29: 55-62.
3. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000; 15: 290-301.
4. Okuda S. Process of tubulointerstitial injury in progressive renal diseases. Clin Exp Nephrol 1999; 3: 65-7.
5. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002; 136: 604-15.
6. Hilgers KF, Dotsch J, Rascher W, Mann JF. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 2004; 19: 956-61.
7. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-56.
8. Skill NJ, Johnson TS, Coutts IG, et al. Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epitheial cells. J Biol Chem 2004; 279: 47754-62.
9. Fraser D, Brunskill N, Ito T, Phillips A. Long-term exposure of proximal tubular epithelial cells to glucose induces transforming growth factor-beta 1 synthesis via an autocrine PDGF loop. Am J Pathol 2003; 163: 2565-74.
10. Fujita H, Omori S, Ishikura K, Hida M, Awazu M. ERK and p38 mediate high-glucose-induced hypertrophy and TGF-beta expression in renal tubular cells. Am J Physiol Renal Physiol 2004; 286: F120-F126.
11. Zhang SL, Tang SS, Chen X, Filep JG, Ingelfinger JR, Chan JS. High levels of glucose stimulate angiotensinogen gene expression via the P38 mitogen-activated protein kinase pathway in rat kidney proximal tubular cells. Endocrinology 2000; 141: 4637-46.
12. Li JH, Huang XR, Zhu HJ, Johnson R, Lan HY. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int 2003; 63: 2010-9.
13. Morrisey K, Steadman R, Williams JD, Phillips AO. Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent. Kidney Int 1999; 55: 160-7.
14. Hellwig-Burgel T, Stiehl DP, Katschinski DM, Marxsen J, Kreft B, Jelkmann W. VEGF production by primary human renal proximal tubular cells: requirement of HIF-1, PI3-kinase and MAPKK-1 signaling. Cell Physiol Biochem 2005; 15: 99-108.
15. Combe C, Burton CJ, Dufourco P, et al. Hypoxia induces intercellular adhesion molecule-1 on cultured human tubular cells. Kidney Int 1997; 51: 1703-9.
16. Drumm K, Gassner B, Silbernagl S, Gekle M. Inhibition of Na superset+/H superset+ exchange decreases albumin-induced NF-kappaB activation in renal proximal tubular cell lines (OK and LLC-PK1 cells). Eur J Med Res 2001; 6: 422-32.
17. Dixon R, Brunskill NJ. Albumin stimulates p44/p42 extracellular-signal-regulated mitogen-activated protein kinase in opossum kidney proximal tubular cells. Clin Sci (Lond) 2000; 98: 295-301.
18. Morigi M, Macconi D, Zoja C, et al. Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. J Am Soc Nephrol 2002; 13: 1179-89.
19. Zoja C, Donadelli R, Colleoni S, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998; 53: 1608-15.
20. Yard BA, Chorianopoulos E, Herr D, van der Woude FJ. Regulation of endothelin-1 and transforming growth factor-beta1 production in cultured proximal tubular cells by albumin and heparan sulphate glycosaminoglycans. Nephrol Dial Transplant 2001; 16: 1769-75.
21. Takaya K, Koya D, Isono M, et al. Involvement of ERK pathway in albumin-induced MCP-1 expression in mouse proximal tubular cells. Am J Physiol Renal Physiol 2003; 284: F1037-F1045.
22. Fan JM, Ng YY, Hill PA, et al. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999; 56: 1455-67.
23. Tian YC, Fraser D, Attisano L, Phillips AO. TGF-beta1-mediated alterations of renal proximal tubular epithelial cell phenotype. Am J Physiol Renal Physiol 2003; 285: F130-F142.
24. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002; 13: 1464-72.
25. Kitamura S, Maeshima Y, Sugaya T, Sugiyama H, Yamasaki Y, Makino H. Transforming growth factor-beta 1 induces vascular endothelial growth factor expression in murine proximal tubular epithelial cells. Nephron Exp Nephrol 2003; 95: e79-e86.
26. Leonard M, Ryan MP, Watson AJ, Schramek H, Healy E. Role of MAP kinase pathways in mediating IL-6 production in human primary mesangial and proximal tubular cells. Kidney Int 1999; 56: 1366-77.
27. Schmouder RL, Strieter RM, Wiggins RC, Chensue SW, Kunkel SL. In vitro and in vivo interleukin-8 production in human renal cortical epithelia. Kidney Int 1992; 41: 191-8.
28. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993; 92: 1366-72.
29. Hannken T, Schroeder R, Zahner G, Stahl RA, Wolf G. Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27(Kip1): role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol 2000; 11: 1387-97.
30. Wolf G, Kalluri R, Ziyadeh FN, Neilson EG, Stahl RA. Angiotensin II induces alpha3(IV) collagen expression in cultured murine proximal tubular cells. Proc Assoc Am Physicians 1999; 111: 357-64.
31. Wolf G, Zahner G, Schroeder R, Stahl RA. Transforming growth factor beta mediates the angiotensin-II-induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells. Nephrol Dial Transplant 1996; 11: 263-9.
32. Vesey DA, Cheung CW, Cuttle L, Endre ZA, Globe G, Johnson DW. Interleukin-1 beta induces human proximal tubule cell injuty, alpha-smooth muscle actin expression and fibronectin production. Kidney Int 2002; 62: 31-40.
33. Wang Y, Rangan GK, Goodwin B, Tay YC, Harris DC. Lipopolysaccharide-induced MCP-1 gene expression in rat tubular epithelial cells is nuclear factor-kappaB dependent. Kidney Int 2000; 57: 2011-21.
34. Wang SN, Hirschberg R. Tubular epithelial cell activation and interstitial fibrosis. The role of glomerular ultrafiltration of growth factors in the nephrotic syndrome and diabetic nephropathy. Nephrol Dial Transplant 1999; 14: 2072-4.
35. Eddy A. Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis 2001; 37: S25-S29.
36. Rossini M, Fogo AB. Mechanisms leading to progression of chronic renal injury: the interstitium. Drug Discov Today 2005; 1: 65-72.
37. Suzuki Y, Ruiz-Ortega M, Egido J. Angiotensin II: a double-edged sword in inflammation. J Nephrol 2000; 13 (Suppl 3): S101-S110.
38. Largo R, Gomez-Garre D, Soto K, et al. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension 1999; 33: 732-9.
39. Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992; 19: 464-74.
40. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-8.
41. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 31: 181-8.
42. Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst 2003; 4: 43-7.
43. Ruilope LM. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Acta Diabetol 2005; 42 (Suppl 1): S33-S41.
44. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003; 24: 225-48.
45. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002; 23: 482-6.
46. Wietrzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99: 95-112.
47. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl 1999; 71: S2-S5.
48. Buemi M, Senatore M, Corica F, et al. Statins and progressive renal disease. Med Res Rev 2002; 22: 76-84.
49. Kim SY, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF. Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. Kidney Int 1995; 48: 363-71.
50. Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 1997; 52: 1016-27.
51. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993; 91: 83-7.
52. Ikeuchi H, Kuroiwa T, Yamashita S, et al. Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: therapeutic implications for tubulointerstitial fibrosis. Nephron Exp Nephrol 2004; 97: e115-e122.
53. Park YS, Guijarro C, Kim Y, et al. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998; 31: 190-4.
54. Park JK, Muller DN, Mervaala EM, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 2000; 58: 1420-30.
55. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003; 46: 843-51.
56. Yokota N, O'Donnell M, Daniels F, et al. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol 2003; 23: 13-7.
57. Joyce M, Kelly C, Winter D, Chen G, Leahy A, Bouchier-Hayes D. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res 2001; 101: 79-84.
58. Rikitake Y, Liao JK. Rho GTPases, stating, and nitric oxide. Circ Res 2005; 97: 1232-5.
59. Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002; 13: 2898-908.
60. Zoja C, Corna D, Rottoli D, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002; 61: 1635-45.
61. Buemi M, Allegra A, Corica F, et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000; 67: 427-31.
62. Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 2002; 17: 798-802.
63. Yasuda G, Kuji T, Hasegawa K, et al. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Ren Fail 2004; 26: 411-8.
64. Furuichi K, Wada T, Iwata Y, et al. Administration of FR167653, a new anti-inflammatory compound, prevents renal ischaemia/reperfusion injury in mice. Nephrol Dial Transplant 2002; 17: 399-407.
65. Kita T, Yamaguchi H, Sato H, Kasai K, Tanaka T, Tanaka N. Role of p38 mitogen-activated protein kinase pathway on renal failure in the infant rat after burn injury. Shock 2004; 21: 535-42.
66. Stambe C, Atkins RC, Tesch GH, et al. Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol 2003; 14: 338-51.
67. Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF, Nikolic-Paterson DJ. The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. J Am Soc Nephrol 2004; 15: 370-9.
68. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 2005; 289: F166-F174.
69. Jo SK, Cho WY, Sung SA, Kim HK, Won NH. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 2005; 67: 458-66.
70. Flanc RS, Ma F, Tesch GH, et al. JNK Blockade Reduces Renal Fibrosis in Unilateral Ureteric Obstruction. J Am Soc Nephrol 2006; 16: 609A.
71. Nagatoya K, Moriyama T, Kawada N, et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61: 1684-95.
72. Teraishi K, Kurata H, Nakajima A, Takaoka M, Matsumura Y. Preventive effect of Y-27632, a selective Rho-kinase inhibitor, on ischemia/ reperfusion-induced acute renal failure in rats. Eur J Pharmacol 2004; 505: 205-11.
73. Satoh S, Yamaguchi T, Hitomi A, et al. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 2002; 455: 169-74.
74. Nishikimi T, Akimoto K, Wang X, et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004; 22: 1787-96.
75. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 2003; 64: 2009-19.
76. Rangan GK, Wang Y, Tay YC, Harris DC. Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999; 56: 118-34.
77. Mudge SJ, Paizis K, Auwardt RB, Thomas RJ, Power DA. Activation of nuclear factor-kappa B by podocytes in the autologous phase of passive Heymann nephritis. Kidney Int 2001; 59: 923-31.
78. Miyajima A, Kosaka T, Seta K, Asano T, Umezawa K, Hayakawa M. Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. J Urol 2003; 169: 1559-63.
79. Tashiro K, Tamada S, Kuwabara N, et al. Attenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy: possible role of nuclear factor kappaB. Int J Mol Med 2003; 12: 587-92.
80. Grygielko ET, Martin WM, Tweed C, et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 2005; 313: 943-51.
81. Gellibert F, de Gouville AC, Woolven J, et al. Discovery of 4-{4-3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. J Med Chem 2006; 49: 2210-21.
82. Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006; 70: 1234-43.
83. Ludewig D, Kosmehl H, Sommer M, Bohmer FD, Stein G. PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res 2000; 299: 97-103.
84. Gilbert RE, Kelly DJ, McKay T, et al. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001; 59: 1324-32.
85. Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 2005; 19: 1-11.
86. Tian W, Zhang Z, Cohen DM. MAPK signaling and the kidney. Am J Physiol Renal Physiol 2000; 279: F593-F604.
87. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000; 47: 185-201.
88. Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Dev 2005; 8: 421-30.
89. de Borst MH, Wassef L, Kelly DJ, van Goor H, Navis G. Mitogen activated protein kinase signaling in the kidney: target for intervention? Signal Transduct 2005; 5: 1-22.
90. Sato H, Tanaka T, Kasai K, Kita T, Tanaka N. Role of p38 mitogen-activated protein kinase on renal dysfunction after hemorrhagic shock in rats. Shock 2005; 24: 488-94.
91. Meldrum KK, Meldrum DR, Hile KL, et al. p38 MAPK mediates renal tubular cell TNF-alpha production and TNF-alpha-dependent apoptosis during simulated ischemia. Am J Physiol Cell Physiol 2001; 281: C563-C570.
92. Park SJ, Jeong KS. Cell-type-specific activation of mitogen-activated protein kinases in PAN-induced progressive renal disease in rats. Biochem Biophys Res Commun 2004; 323: 1-8.
93. Stambe C, Atkins RC, Hill PA, Nikolic-Paterson DJ. Activation and cellular localization of the p38 and JNK MAPK pathways in rat crescentic glomerulonephritis. Kidney Int 2003; 64: 2121-32.
94. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 2002; 23: 40-5.
95. de Laszlo SE, Visco D, Agarwal L, et al. Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg Med Chem Lett 1998; 8: 2689-94.
96. Wilson KP, Fitzgibbon MJ, Caron PR, et al. Crystal structure of p38 mitogen-activated protein kinase. J Biol Chem 1996; 271: 27696-700.
97. Wang Z, Canagarajah BJ, Boehm JC, et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998; 6: 1117-28.
98. Kéri G, Orfi L, Eros D, et al. Signal Transduction Therapy with Rationally Designed Kinase Inhibitors. Curr Signal Transduct Ther 2006; 1: 67-95.
99. Pat B, Yang T, Kong C, Watters D, Johnson DW, Globe G. Activation of ERK in renal fibrosis after unilateral ureteral obstruction: modulation by antioxidants. Kidney Int 2005; 67: 931-43.
100. Masaki T, Stambe C, Hill PA, Dowling J, Atkins RC, Nikolic-Paterson DJ. Activation of the extracellular-signal regulated protein kinase pathway in human glomerulopathies. J Am Soc Nephrol 2004; 15: 1835-43.
101. Pombo CM, Bonventre JV, Avruch J, Woodgett JR, Kyriakis JM, Force T. The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion. J Biol Chem 1994; 269: 26546-51.
102. Hagiwara M, Murakami H, Ura N, et al. Renal protective role of bradykinin B1 receptor in stroke-prone spontaneously hypertensive rats. Hypertens Res 2004; 27: 399-408.
103. Nishiyama A, Yao L, Nagai Y, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43: 841-8.
104. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J 2000; 348 (Pt 2): 241-55.
105. Sharpe CC, Hendry BM. Signaling: focus on Rho in renal disease. J Am Soc Nephrol 2003; 14: 261-4.
106. Ruiz-Ortega M, Ruperez M, Esteban V, et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 2006; 21: 16-20.
107. Heusinger-Ribeiro J, Eberlein M, Wahab NA, Goppelt-Struebe M. Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP. J Am Soc Nephrol 2001; 12: 1853-61.
108. Romano F, Chiarenza C, Palombi F, et al. Platelet-derived growth factor-BB-induced hypertrophy of peritubular smooth muscle cells is mediated by activation of p38 MAP-kinase and of Rho-kinase. J Cell Physiol 2006; 207: 123-31.
109. Masamune A, Satoh M, Kikuta K, Suzuki N, Shimosegawa T. Endothelin-1 stimulates contraction and migration of rat pancreatic stellate cells. World J Gastroenterol 2005; 11: 6144-51.
110. Patel S, Takagi KI, Suzuki J, et al. RhoGTPase activation is a key step in renal epithelial mesenchymal transdifferentiation. J Am Soc Nephrol 2005; 16: 1977-84.
111. Moriyama T, Nagatoya K. The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis. Drug News Perspect 2004; 17: 29-34.
112. Saltis J. TGF-beta: receptors and cell cycle arrest. Mol Cell Endocrinol 1996; 116: 227-32.
113. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002; 13: 2600-10.
114. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000; 14: 627-44.
115. Lutz M, Knaus P. Integration of the TGF-beta pathway into the cellular signalling network. Cell Signal 2002; 14: 977-88.
116. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-84.
117. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-7.
118. Kaneto H, Morrissey J, Klahr S. Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993; 44: 313-21.
119. Fukuda K, Yoshitomi K, Yanagida T, Tokumoto M, Hirakata H. Quantification of TGF-beta1 mRNA along rat nephron in obstructive nephropathy. Am J Physiol Renal Physiol 2001; 281: F513-F521.
120. Diamond JR, Kees-Folts D, Ding G, Frye JE, Restrepo NC. Macrophages, monocyte chemoattractant peptide-1, and TGF-beta 1 in experimental hydronephrosis. Am J Physiol 1994; 266: F926-F933.
121. Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA. Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am J Pathol 1992; 141: 1381-96.
122. Geleilete TJ, Melo GC, Costa RS, Volpini RA, Soares TJ, Coimbra TM. Role of myofibroblasts, macrophages, transforming growth factor-beta endothelin, angiotensin-II, and fibronectin in the progression of tubulointerstitial nephritis induced by gentamicin. J Nephrol 2002; 15: 633-42.
123. Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M, Fujishima M. TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy. Kidney Int 1994; 45: 525-36.
124. Li J, Campanale NV, Liang RJ, Deane JA, Bertram JF, Ricardo SD. Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am J Pathol 2006; 169: 1527-40.
125. Goumenos DS, Tsamandas AC, Kalliakmani P, et al. Expression of apoptosis-related proteins bcl-2 and bax along with transforming growth factor (TGF-beta1) in the kidney of patients with glomerulonephritides. Ren Fail 2004; 26: 361-7.
126. Zhou Y, Takahashi G, Shinagawa T, et al. Increased transforming growth factor-beta1 and tubulointerstitial fibrosis in rats with congenital hydronephrosis. Int J Urol 2002; 9: 491-500.
127. Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108: 807-16.
128. Choi ME, Ballermann BJ. Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors. J Biol Chem 1995; 270: 21144-50.
129. Vuruskan H, Caliskan Z, Kordan Y, Ozakin C, Yavascaoglu I, Oktay B. Elevated plasma concentrations of transforming growth factor-beta 1 in patients with unilateral ureteral obstruction. Urol Res 2005; 33: 465-9.
130. Goumenos DS, Tsamandas AC, Oldroyd S, et al. Transforming growth factor-beta(1) and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease. Nephron 2001; 87: 240-8.
131. Agarwal R, Siva S, Dunn SR, Sharma K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002; 39: 486-92.
132. Pimentel JL, Jr., Sundell CL, Wang S, Kopp JH, Montero A, Martinez-Maldonado M. Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy. Kidney Int 1995; 48: 1233-46.
133. Yokoi H, Sugawara A, Mukoyama M, et al. Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis. Am J Kidney Dis 2001; 38: S134-S138.
134. Qi W, Twigg S, Chen X, et al. Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fibrosis. Am J Physiol Renal Physiol 2005; 288: F800-F809.
135. Callahan JF, Burgess JL, Fornwald JA, et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem 2002; 45: 999-1001.
136. Yakymovych I, Engstrom U, Grimsby S, Heldin CH, Souchelnytskyi S. Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF beta type I receptor kinase. Biochemistry 2002; 41: 11000-7.
137. Inman GJ, Nicolas FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002; 62: 65-74.
138. Laping NJ, Grygielko E, Mathur A, et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 2002; 62: 58-64.
139. DaCosta BS, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004; 65: 744-52.
140. Tojo M, Hamashima Y, Hanyu A, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epitheial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci 2005; 96: 791-800.
141. Bonniaud P, Margetts PJ, Kolb M, et al. Progressive Transforming Growth Factor {beta} 1-induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor. Am J Respir Crit Care Med 2005; 171: 889-98.
142. de Gouville AC, Boullay V, Krysa G, et al. Inhibition of TGF-beta signaling an ALK5 inhibitor protects rats from dimethylnifrosamine-induced liver fibrosis. Br J Pharmacol 2005; 145: 166-77.
143. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 2002; 398: 284-90.
144. Reigstad LJ, Varhaug JE, Lillehaug JR. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 2005; 272: 5723-41.
145. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15: 255-73.
146. Abboud HE. Role of platelet-derived growth factor in renal injury. Annu Rev Physiol 1995; 57: 297-309.
147. Gesualdo L, Di PS, Milani S, et al. Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study. J Clin Invest 1994, 94: 50-8.
148. Matsuda M, Shikata K, Makino H, et al. Gene expression of PDGF and PDGF receptor in various forms of glomerulonephritis. Am J Nephrol 1997; 17: 25-31.
149. Iida H, Seifert R, Alpers CE, et al. Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc Natl Acad Sci U S A 1991; 88: 6560-4.
150. Tang WW, Ulich TR, Lacey DL, et al. Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am J Pathol 1996; 148: 1169-80.
151. Langham RG, Kelly DJ, Maguire J, Dowling JP, Gilbert RE, Thomson NM. Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol Dial Transplant 2003; 18: 1392-6.
152. Eitner F, Ostendorf T, Kretzler M. et al. PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J Am Soc Nephrol 2003; 14: 1145-53.
153. Taneda S, Hudkins KL, Topouzis S, et al. Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury. J Am Soc Nephrol 2003; 14: 2544-55.
154. Ostendorf T, van Roeyen CR, Peterson JD, et al. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2003; 14: 2237-47.
155. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999; 276: L311-L318.
156. Rice AB, Moomaw CR, Morgan DL, Bonner JC. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 1999; 155: 213-21.
157. Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R. Dominant-negative soluble PDGF-beta receptor inhibits hepatìc stellate cell activation and attenuates liver fibrosis. Lab Invest 2004; 84: 766-77.
158. Gesualdo L, Di PS, Ranieri E, Schena PP. Trapidil inhibits human mesangial cell proliferation: effect on PDGF beta-receptor binding and expression. Kidney Int 1994; 46: 1002-9.
159. Razzaque MS, Cheng M, Taguchi T. Suppression of mesangial-cell proliferation by trapidil in glomerulonephritis induced by anti-thymocyte serum in rats. J Int Med Res 1995; 23: 458-66.
160. Buyukafsar K, Yazar A, Dusmez D, Ozturk H, Polat G, Levent A. Effect of trapidil, an antiplatelet and vasodilator agent on gentamicin-induced nephrotoxicity in rats. Pharmacol Res 2001; 44: 321-8.
161. Nakagawa T, Sasahara M, Haneda M, et al. Role of PDGF B-chain and PDGF receptors in rat tubular regeneration after acute injury. Am J Pathol 1999; 155: 1689-99.
162. Gazit A, Yee K, Uecker A, et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem 2003; 11: 2007-18.
163. Iwamoto H, Nakamuta M, Tada S, Sugimoto R, Enjoji M, Nawata H. Platelet-derived growth factor receptor tyrosine kinase inhibitor AG1295 attenuates rat hepatic stellate cell growth. J Lab Clin Med 2000; 135: 406-12.
164. Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev 2004; 15: 229-35.
165. Lassila M, Jandeleit-Dahm K, Seah KK, et al. Imatinib, attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005; 16: 363-73.
166. Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005; 201: 925-35.
167. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-34.
168. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-42.
169. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-224.
170. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-59.
171. Sakurai H, Hisada Y, Ueno M, Sugiura M, Kawashima K, Sugita T. Activation of transcription factor NF-kappa B in experimental glomerulonephritis in rats. Biochim Biophys Acta 1996; 1316: 132-8.
172. Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F, Egido J. Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension 2001; 37: 1171-8.
173. Tamada S, Nakatani T, Asai T, et al. Inhibition of nuclear factor-kappaB activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy. Kidney Int 2003; 63: 306-14.
174. Gong R, Rifai A, Tolbert EM, Biswas P, Centracchio JN, Dworkin LD. Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol 2004; 15: 2868-81.
175. Lopez-Franco O, Suzuki Y, Sanjuan G, et al. Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis. Am J Pathol 2002; 161: 1497-505.
176. Sakai N, Wada T, Furuichi K, et al. p38 MAPK phosphorylation and NF-kappa B activation in human crescentic glomerulonephritis. Nephrol Dial Transplant 2002; 17: 998-1004.
177. Sakai N, Wada T, Furuichi K, et al. Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis 2005; 45: 54-65.
178. Aggarwal BB, Sethi G, Nair A, Ichikawa H. Nuclear Factor-?B: A Holy Grail in Cancer Prevention and Therapy. Curr Signal Transduct Ther 2006; 1: 25-52.
179. Volpini RA, Costa RS, da Silva CG, Coimbra TM. Inhibition of nuclear factor-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin. Nephron Physiol 2004; 98: 97-106.
180. Sakurai H, Shigemori N, Hisada Y, Ishizuka T, Kawashima K, Sugita T. Suppression of NF-kappa B and AP-1 activation by glucocorticoids in experimental glomerulonephritis in rats: molecular mechanisms of antinephritic action. Biochim Biophys Acta 1997; 1362: 252-62.
181. Auwardt RB, Mudge SJ, Chen CG, Power DA. Regulation of nuclear factor kappaB by corticosteroids in rat mesangial cells. J Am Soc Nephrol 1998; 9: 1620-8.
182. Umezawa K, Chaicharoenpong C. Molecular design and biological activities of NF-kappaB inhibitors. Mol Cells 2002; 14: 163-7.
183. Suzuki K, Susaki H, Okuno S, Sugiyama Y. Renal drug targeting using a vector "alkylglycoside". J Pharmacol Exp Ther 1999; 288: 57-64.
184. Shirota K, Kato Y, Suzuki K, Sugiyama Y. Characterization of novel kidney-specific delivery system using an alkylglucoside vector. J Pharmacol Exp Ther 2001; 299: 459-67.
185. Kamada H, Tsutsumi Y, Sato-Kamada K, et al. Synthesis of a poly(vinyl-pyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting. Nat Biotechnol 2003; 21: 399-404.
186. Franssen EJ, Koiter J, Kuipers CA, et al. Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. J Med Chem 1992; 35: 1246-59.
187. Haas M, Kluppel AC, Wartna ES, et al. Drug-targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo. Kidney Int 1997; 52: 1693-9.
188. Kok RJ, Grijpstra F, Walthuis RB, Moolenaar F, de Zeeuw D, Meijer DK. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme. J Pharmacol Exp Ther 1999; 288: 281-5.
189. Prakash J, van Loenen-Weemaes AM, Haas M, et al. Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme. Drug Metab Dispos 2005; 33: 683-8.
190. Windt WA, Prakash J, Kok RJ, et al. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis. J Renin Angiotensin Aldosterone Syst 2004; 5: 197-202.
191. Prakash J, Sandovici M, Saluja V, et al. Intracellular Delivery of the P38 MAPK Inhibitor SB202190 in Renal Tubular Cells: a Novel Strategy to Treat Renal Fibrosis. J Pharmacol Exp Ther 2006; 319: 8-19.
192. van der Wouden EA, Sandovici M, Henning RH, de Zeeuw D, Deelman LE. Approaches and methods in gene therapy for kidney disease. J Pharmacol Toxicol Methods 2004; 50: 13-24.
193. Wolf WC, Yoshida H, Agata J, Chao L, Chao J. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 2000; 58: 730-9.
194. Xia CF, Bledsoe G, Chao L, Chao J. Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. Am J Physiol Renal Physiol 2005; 289: F622-F631.
195. Wang C, Dobrzynski E, Chao J, Chao L. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol 2001; 280: F964-F971.
196. Zhang JJ, Yoshida H, Chao L, Chao J. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. Hum Gene Ther 2000; 11: 1817-27.
197. Zhou A, Ueno H, Shimomura M, et al. Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int 2003; 64: 92-101.
198. Hou CC, Wang W, Huang XR, et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol 2005; 166: 761-71.
199. Lan HY, Mu W, Tomita N, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003; 14: 1535-48.
200. Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc Nephrol 2004; 15: 2637-47.
201. Yang J, Dai C, Liu Y. Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther 2001; 8: 1470-9.
202. Yazawa K, Isaka Y, Takahara S, et al. Direct transfer of hepatocyte growth factor gene into kidney suppresses cyclosporin A nephrotoxicity in rats. Nephrol Dial Transplant 2004; 19: 812-6.
203. Gao X, Mae H, Ayabe N, et al. Hepatocyte growth factor gene therapy retards the progression of chronic obstructive nephropathy. Kidney Int 2002; 62: 1238-48.
204. Shimizu H, Maruyama S, Yuzawa Y, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 2003; 14: 1496-505.
205. Wada T, Furuichi K, Sakai N, et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 2004; 15: 940-8.
206. Yokoi H, Mukoyama M, Nagae T, et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004; 15: 1430-40.
207. Takabatake Y, Isaka Y, Mizui M, et al. Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther 2005; 12: 965-73.
208. Kushibiki T, Nagata-Nakajima N, Sugai M, Shimizu A, Tabata Y. Delivery of plasmid DNA expressing small interference RNA for TGF-beta type II receptor by cationized gelatin to prevent interstitial renal fibrosis. J Control Release 2005; 105: 318-31.
209. Hwang M, Kim HJ, Noh HJ, et al. TGF-beta1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction. Exp Mol Pathol 2006; 81: 48-54.
210. Tipping PG, Kitching AR, Huang XR, Mutch DA, Holdsworth SR. Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol 1997; 27: 530-7.
211. Huang XR, Kitching AR, Tipping PG, Holdsworth SR. Interleukin-10 inhibits macrophage-induced glomerular injury. J Am Soc Nephrol 2000; 11: 262-9.
212. Kitching AR, Katerelos M, Mudge SJ, Tipping PG, Power DA, Holdsworth SR. Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis. Clin Exp Immunol 2002; 128: 36-43.
213. Lai PC, Smith J, Bhangal G, et al. Interleukin-11 reduces renal injury and glomerular NF-kappa B activity in murine experimental glomerulonephritis. Nephron Exp Nephrol 2005; 101: e146-e154.
214. Vukicevic S, Basic V, Rogic D, et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998; 102: 202-14.
215. Simon M, Maresh JG, Harris SE, et al. Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Am J Physiol 1999; 276: F382-F389.
216. Patel SR, Dressler GR. BMP7 signaling in renal development and disease. Trends Mol Med 2005; 11: 512-8.
217. Hruska KA, Guo G, Wozniak M, et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 2000; 279: F130-F143.
218. Morrissey J, Hruska K, Guo G, Wang S, Chen Q, Klahr S. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 2002; 13 (Suppl 1): S14-S21.
219. Zeisberg M, Bottiglio C, Kumar N, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 2003; 285: F1060-F1067.
220. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 2004; 287: F7-16.
221. Yang J, Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2003; 284: F349-F357.
222. Gong R, Rifai A, Tolbert EM, Centracchio JN, Dworkin LD. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol 2003; 14: 3047-60.
223. Johnson TS, Griffin M, Thomas GL, et al. The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest 1997; 99: 2950-60.
224. Skill NJ, Griffin M, el Nahas AM, et al. Increases in renal epsilon-(gamma-glutamyl)-lysine crosslinks result from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy: pathologic implicationg. Lab Invest 2001; 81: 705-16.